Verrica制药 VRCA 深 沪
等待开盘 04-02 09:30:00 美东时间
5.54
+0.250
+4.73%
华盛通- 最 高5.60
- 今 开5.31
- 成交量 7.09万股
- 最 低 4.99
- 昨 收 5.29
- 总市值 9517.05万
- 52周最高 9.8212
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 3.28
- 委 比 36.10%
- 总股本 1717.88万
- 历史最高 232.90
- 量 比 1.39
- 振 幅 11.53%
- 历史最低 3.816
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Verrica Pharmaceuticals Q4 Adj. EPS $(0.51) Beats $(0.79) Estimate, Sales $5.092M Beat $4.525M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.79) by 35.77 percent. This is a 71.67 percent increase over losses of $(1.80) per
03-11 20:01
Earnings Scheduled For March 11, 2026
Companies Reporting Before The Bell • Sprinklr (NYSE:CXM) is estimated to repor...
03-11 19:11
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Verrica Pharmaceuticals Inc. will host a conference call and live webcast on March 11, 2026, at 8:30 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and provide a corporate update. Participants can join by dialing 1-800-343-4136 (US) or 1-203-518-9843 (international) with conference ID: VERRICA, or via webcast on the investor relations section of www.verrica.com. The webcast will be archived for 90 days. Verrica is a de...
03-05 13:00
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Verrica Pharmaceuticals' CEO, Jayson Rieger, PhD, MBA, will present at the TD Cowen 46th Annual Healthcare Conference in Boston on March 2, 2026, at 10:30am ET. The event will be available via live webcast accessible through the provided links or the Investors section of Verrica's website. Verrica develops medications for skin diseases, including YCANTH® (VP-102) for molluscum contagiosum and common warts, and is collaborating with Lytix Biopharm...
02-23 13:00
Verrica Pharma Announces Launch Of YCANTH In Japan By Its Partner, Torii Pharma, For Treatment Of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH®
02-09 21:12
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
Verrica Pharmaceuticals Inc. announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd., for treating molluscum contagiosum. This represents a significant milestone for Verrica as they expand their global strategy for YCANTH across various dermatologic indications. YCANTH, a drug-device combination product, has shown positive safety and efficacy in Phase 3 trials, addressing a significant unmet need in Japan with few a...
02-09 13:00
Verrica Pharmaceuticals Files Initial Beneficial Ownership Statement for BKB Growth Investments
Verrica Pharmaceuticals Files Initial Beneficial Ownership Statement for BKB Growth Investments Verrica Pharmaceuticals Inc. has filed an initial statement of beneficial ownership, disclosing BKB Growth Investments, LLC as the beneficial owner. The full filing can be accessed through the link below.
01-27 05:24
Verrica Pharma Announces First Patient Dosed In December 2025 In Global Phase 3 Program Evaluating YCANTH For Treatment Of Common Warts
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity–– Verrica has
01-07 21:09
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals announced the initiation of a global Phase 3 program for YCANTH (VP-102) to treat common warts, with the first patient dosed in December 2025. YCANTH has shown promising results in a Phase 2 trial, achieving 51% complete clearance of warts. The company retains commercial rights for YCANTH outside Japan. Common warts affect over 22 million people in the U.S., with significant commercial potential. Verrica expects YCANTH to ...
01-07 13:00
Verrica Pharmaceuticals Adds Caligan Partner to Board
The latest update is out from Verrica Pharmaceuticals ( ($VRCA) ). On December ...
2025-12-30 19:27
